FR EN
Share this page

Norbert VEY

MD

    General Director at Institut Paoli Calmettes | Professor of Hematology at Aix-Marseille University

AMU, IPC

The new immunotherapy antibodies currently developed by biotech companies from Marseille reflect the teams' dynamism and the extraordinary local potential.

As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the creatity and efficiency of the Marseille’s network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).

MI will enable the development of original and highly innovative approaches in immunotherapy, based on these three pillars. New molecules currently developed by biotech companies from Marseille reflect the teams’ dynamism and the extraordinary local potential.

#clinique #recherche